Microalbuminuria as an intermediate endpoint in essential hypertension: Evidence is coming

Journal of Hypertension

Volumn 22, Issue 9, 2004, Pages 1679-1681

  Redon, Josep ^a   Ruilope, Luis M ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE MARKER; EDITORIAL; FOLLOW UP; GENETICS; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SMOKING; URINALYSIS;

EID: 4344568426     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200409000-00010     Document Type: Editorial

References (37)

1. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
2. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310:356-360.
3. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Islington diabetes survey. Lancet 1988; 2:530-533.
4. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300:297-300.
5. Haffner SM, Stern MP, Kozlowski MK, Hazuda HP, Mitchell BD, Patterson JK. Microalbuminuria. Potential marker for increased cardiovascular factors in non-diabetic subjects? Atherosclerosis 1990; 10:727-731.
6. Ruilope LM, Campo C, Rodriguez-Artalejo F, Garcia-Robles R, Rodicio JL. Blood pressure and renal function. Therapeutic implications. J Hypertens 1996; 14:1259-1263.
7. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19:1992-1997.
8. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19:617-624.
9. Roest M, Banga JD, Janssen WM, Grobbee DE, Sixma JJ, de Jong PE, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103:3057-3061.
10. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al., for the HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
11. Romunstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H. Microalbuminuria and all-cause mortality in treated hypertensive individuals. Does sex matter?. The Nord-Trondelag Health Study (HUNT), Norway. Circulation 2003; 108:2783-2789.
12. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Ann Intern Med 2003; 139:901-906.
13. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al., for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
14. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
15. Redon J, Williams B. Microalbuminuria in essential hypertension. Redefining the threshold. J Hypertens 2002; 20:353-355.
16. Ibsen H, Wachtell K, Olsen MH, Borch-Johsen K, Lindholm LH, Mogensen CE, et al. Does microalbuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22:1805-1811.
17. Redon J. Renal protection with antihypertensive drugs. Insights from the microalbuminuria studies. J Hypertens 1998; 16:2091-2100.
18. Erley CM, Haefele U, Heyne N, Braun N, Risler T. Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 1993; 21:810-815.
19. Segura J, Christianse E, Campo C, Ruilope LM. How to titrate ACE inhibitors and angiotensin receptor blockers in renap patients. Curr Hypertens Reports 2003; 5:426-429.
20. Giaconi S, Levanti C, Fommei E, Innocenti F, Seghieri G, Palla G, et al. Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension. Am J Hypertens 1989; 2:259-261.
21. Gerber LM, Smukler C, Alderman MH. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and non-white subjects. Arch Intern Med 1992; 152:373-377.
22. Redon J, Lozano JV, Liao Y, Miralles A, Baldo E, Cooper RS. Factors related to the presence of microalbuminuria in essential hypertension. Am J Hypertens 1994; 7:801-807.
23. Martinez MA, Moreno A, Aguirre de Carcer A, Cabrera R, Rocha R, Torre A, et al., for the MAPA-Madrid Working Group. Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study. J Hypertens 2001; 19:319-326.
24. Bianchi S, Bigazzi R, Valtriani C, Chiaponni I, Sgherri G, Baldari G, et al. Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension 1994; 23:681-687.
25. Redon J, Miralles A, Pascual JM, Baldo E, Garcia Robles R, Carmena R. Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. J Hypertens 1997; 15:79-86.
26. de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL, for the PREVEND study group. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 26 (suppl 4):S21-S24.
27. Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133:585-591.
28. Fernandez-Llama P, Poch E, Oriola J, Botey A, Coll E, Darnell A, et al. Angiotensin converting enzyme I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 1998; 53:1743-1747.
29. Redon J, Chaves FJ, Liao YL, Pascual JM, Rovira E, Armengod ME, Cooper RS. Influence of the I/D polymorphism of the angiotensin-converting enzyme gene on the outcome of microalbuminuria in essential hypertension. Hypertension 2000; 35:490-495.
30. Ruilope LM, Alcazar JM, Hernandez E, Rodicio JL. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 1994; 45 (suppl 45):S171-S173.
31. Sievert-Delle A, Ljungman S, Hartford M, Wikstrand J. Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. Am J Hypertens 1996; 9:841-849.
32. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39:794-798.
33. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 2001; 21:449-454.
34. Sinzinger H, Kritz H, Furberg CD. Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance. Med Sci Monit 2003; 9:PI88-PI92.
35. Roberts AW, Thomas A, Rees A, Evans M. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Curt Opin Lipidol 2003; 14:567-573.
36. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001; 50:1193-1196.
37. Bigazzi R, Blanchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325-1333.